XML 151 R94.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Principal alliances - Collaboration agreements on human therapeutic antibodies (Details) € in Millions, $ in Millions |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | ---
Apr. 01, 2020 | Jul. 01, 2015 agreement | Jul. 31, 2023 EUR (€) | Nov. 30, 2022 EUR (€) | Nov. 30, 2007 agreement | Mar. 31, 2022 | Dec. 31, 2022 Rate | Dec. 31, 2024 EUR (€) Rate | Dec. 31, 2023 EUR (€) Rate | Dec. 31, 2023 USD ($) Rate | Dec. 31, 2022 EUR (€) bond | Dec. 31, 2022 USD ($) bond | Dec. 31, 2015
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales | € |  |  |  |  |  |  |  | € 41,081 | € 37,817 | [1] |  | € 37,651 | [1] |  |
US |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales | € |  |  |  |  |  |  |  | € 19,986 | € 17,262 | [2] |  | € 16,986 | [3] |  |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of agreements signed | agreement |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |
Phase III costs, responsibility percentage |  |  |  |  |  |  |  | 80.00% |  |  |  |  |  |  |
Phase III costs, responsibility percentage for Regeneron |  |  |  |  |  |  |  | 20.00% |  |  |  |  |  |  |
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) |  |  |  |  |  | 10.00% | 20.00% |  |  |  |  |  |  |  |
Percentage of cumulative development costs reimbursed |  |  |  |  |  |  |  | 50.00% |  |  |  | 50.00% |  | 50.00% |
Period before scheduled launch date |  |  |  |  |  |  |  | 24 months |  |  |  |  |  |  |
Number of payments | bond |  |  |  |  |  |  |  |  |  |  |  | 2 |  | 2 |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, first achievement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment related to attainment of goal |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50 |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, first achievement | Antibodies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,000 |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, second achievement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment related to attainment of goal |  |  |  |  |  |  |  |  |  |  |  |  |  | 50 |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, second achievement | Antibodies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,500 |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Prior agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) | Rate |  |  |  |  |  |  | 10.00% | 10.00% |  |  |  |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | New agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) | Rate |  |  |  |  |  |  |  | 20.00% | 20.00% |  | 20.00% |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales Of Antibodies, Third Achievement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment related to attainment of goal |  |  |  |  |  |  |  |  |  |  | $ 50 |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales Of Antibodies, Third Achievement | Antibodies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  |  |  | $ 3,000 |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | US |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of profits and losses arising from commercial operations |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Outside the United States |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of losses arising from commercial operations |  |  |  |  |  |  |  | 55.00% |  |  |  |  |  |  |
Royalty expense, percentage (percentage) | 5.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Outside the United States | Bottom of range |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of profits arising from commercial operations |  |  |  |  |  |  |  | 55.00% |  |  |  |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Outside the United States | Top of range |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of profits arising from commercial operations |  |  |  |  |  |  |  | 65.00% |  |  |  |  |  |  |
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of agreements signed | agreement |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.00%
Percentage of cumulative development costs reimbursed |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00%
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Major Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from collaboration agreements | € |  |  |  |  |  |  |  | € 117 | € 196 |  |  | € 952 |  |  |
AstraZeneca | Antibodies Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreements, regulatory milestone payment | € |  |  | € 65 | € 25 |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements, Amount Paid | € |  |  |  |  |  |  |  | € 25 |  |  |  |  |  |  |
[1] | Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] | (a)Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] | (a)Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

X
- Definition The amount of revenue arising from the sale of goods. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreements, Amount Paid + References No definition available. + Details
Name: | sny_CollaborationAgreementsAmountPaid
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreements, Regulatory Milestone Payment + References No definition available. + Details
Name: | sny_CollaborationAgreementsRegulatoryMilestonePayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Disclosure of detailed information about Principal Alliances [Line Items] + References No definition available. + Details
Name: | sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Agreements Signed + References No definition available. + Details
Name: | sny_NumberOfAgreementsSigned
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Payments + References No definition available. + Details
Name: | sny_NumberOfPayments
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment Related To Attainment Of Goal + References No definition available. + Details
Name: | sny_PaymentRelatedToAttainmentOfGoal
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of cumulative development costs reimbursed. + References No definition available. + Details
Name: | sny_PercentageOfCumulativeDevelopmentCostsReimbursed
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Losses Arising From Commercial Operations + References No definition available. + Details
Name: | sny_PercentageOfLossesArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of profit share on counter parties profit. + References No definition available. + Details
Name: | sny_PercentageOfProfitShareOnCounterpartiesProfit
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of profits and losses arising from commercial operations. + References No definition available. + Details
Name: | sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Profits Arising From Commercial Operations + References No definition available. + Details
Name: | sny_PercentageOfProfitsArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Second Part Of Development Costs Funded + References No definition available. + Details
Name: | sny_PercentageOfSecondPartOfDevelopmentCostsFunded
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of second part of development costs funded by other party. + References No definition available. + Details
Name: | sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period Before Launch Date During Which Commercial Expenses Of Antibodies Co-Developed Under License Agreement Are Shared + References No definition available. + Details
Name: | sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared
Namespace Prefix: | sny_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds From Collaboration Agreements + References No definition available. + Details
Name: | sny_ProceedsFromCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty Expense, Percentage + References No definition available. + Details
Name: | sny_RoyaltyExpensePercentage
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesFirstAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sny_AntibodiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesSecondAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_TypesOfAgreementAxis=sny_PriorAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_TypesOfAgreementAxis=sny_NewAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesThirdAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_OutsideUnitedStatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sny_MajorCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |